TG Therapeutics
TG Therapeutics works on 4 rare diseases tracked on Trial Friend, including Gastrointestinal Stromal Tumor, Hodgkin Lymphoma, Multiple Sclerosis and 1 more, with 12 active clinical trials (9 recruiting) and 1 FDA-approved rare disease drug.
TG Therapeutics is a biotechnology company built around a single antibody, ublituximab, that it has been developing since 2012. The company took shape when a small private startup holding a license to the antibody merged into a public shell, Manhattan Pharmaceuticals, and took the TG Therapeutics name that year under founder and CEO Michael Weiss. For most of its first decade TG was a cancer company, and that chapter ended badly: in 2022 it withdrew its approved lymphoma pill Ukoniq (umbralisib) from the market and pulled a pending application in chronic lymphocytic leukemia after a large trial showed a survival imbalance. TG then bet everything on multiple sclerosis, moved its headquarters from New York to Morrisville, North Carolina, and today trades on Nasdaq under the ticker TGTX.
The bet paid off. BRIUMVI (ublituximab-xiiy) was approved by the FDA on December 28, 2022 for relapsing forms of multiple sclerosis. It works by depleting B cells, the immune cells that drive much of the inflammation in MS, through a marker on their surface called CD20, and its main practical advantage over older B cell therapies is speed: after the first two starter doses, maintenance treatment is a one-hour infusion every six months. Sales have grown quickly, reaching $594 million in the U.S. in 2025, and TG expects roughly $890 to $905 million in 2026. Neuraxpharm sells the drug in Europe, where it was approved in June 2023. In May 2026 the Phase 3 ENHANCE study showed that a single 600 mg infusion on day one delivers the same drug exposure as the current two-step start, and a Phase 3 trial of a subcutaneous injection version, designed for dosing every two or three months, is fully enrolled with results expected around the end of 2026 or early 2027. A Phase 2/3 study in children ages 10 to 17 with relapsing MS began in July 2026.
For the rare disease community, the program to watch is myasthenia gravis. In June 2026 TG reported that 9 of 11 patients with anti-AChR antibody-positive myasthenia gravis in an early study of subcutaneous BRIUMVI reached a clinically meaningful improvement in daily-living symptoms at 24 weeks, and in July 2026 it started a randomized, placebo-controlled Phase 2 trial (NCT07673744) that the company describes as potentially registration-directed. The design is unusual: every patient first receives a round of efgartigimod, an approved FcRn blocker that lowers antibody levels quickly, and those who respond are then randomized to BRIUMVI or placebo to see which group stays well longer. Results are expected in 2028. TG is also testing BRIUMVI in treatment-resistant schizophrenia and, through a license with Precision BioSciences, an off-the-shelf CD19 CAR-T cell therapy called azer-cel in progressive multiple sclerosis and other B cell autoimmune diseases, with the first data expected in the second half of 2026.
TG Therapeutics Drug Pipeline
TG Therapeutics has 12 active clinical trials across 4 development stages, with 9 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
TG Therapeutics Clinical Trials (12)
Active and recruiting clinical trials sponsored by TG Therapeutics, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only TG Therapeutics. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Gastrointestinal Stromal Tumor. Turn any of these off from the link in every email.
TG Therapeutics FDA-Approved Drugs (1)
Medications developed or marketed by TG Therapeutics that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| UBLITUXIMAB CD20-directed Cytolytic Antibody [EPC] | BRIUMVI intravenous | Dec 28, 2022 |
TG Therapeutics Trial Locations
TG Therapeutics clinical trials are running at 353 sites in 15 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (4)
Diseases targeted by TG Therapeutics's clinical trial and drug development programs
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, arising from the interstitial cells of Cajal or their precursors. Most GISTs are driven by...
Hodgkin lymphoma is a cancer of the lymphatic system characterized by the presence of abnormal Reed-Sternberg cells. It typically starts in lymph nodes in the neck, chest, or armpits and can spread to...
Multiple sclerosis is a chronic autoimmune disease where the immune system attacks the protective myelin sheath surrounding nerve fibers in the brain and spinal cord. This disrupts communication betwe...
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies attack acetylcholine receptors at the neuromuscular junction, preventing proper m...
Patient Resources
Organizations and resources related to TG Therapeutics's rare disease focus areas
Frequently Asked Questions About TG Therapeutics
Common questions about TG Therapeutics's rare disease programs, clinical trials, and treatments.